PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression. (2017)

First Author: Shah V
Attributed to:  King's Health Partners Confidence in Concept funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1186/s13058-016-0789-y

PubMed Identifier: 28095868

Publication URI: http://europepmc.org/abstract/MED/28095868

Type: Journal Article/Review

Volume: 19

Parent Publication: Breast cancer research : BCR

Issue: 1

ISSN: 1465-5411